Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 22 | 2024 | 5717 | 0.910 |
Why?
|
Yttrium Radioisotopes | 5 | 2015 | 115 | 0.830 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 1437 | 0.820 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 11 | 2015 | 696 | 0.780 |
Why?
|
Hodgkin Disease | 8 | 2022 | 1384 | 0.730 |
Why?
|
Lymphoma, B-Cell | 8 | 2021 | 945 | 0.560 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2021 | 11878 | 0.500 |
Why?
|
Transplantation, Autologous | 14 | 2023 | 2120 | 0.450 |
Why?
|
Data Mining | 1 | 2019 | 563 | 0.450 |
Why?
|
Graft vs Host Disease | 8 | 2024 | 3049 | 0.440 |
Why?
|
Antibodies, Monoclonal | 11 | 2015 | 9263 | 0.430 |
Why?
|
Therapeutics | 1 | 2013 | 113 | 0.410 |
Why?
|
Guillain-Barre Syndrome | 1 | 2014 | 127 | 0.400 |
Why?
|
Remission Induction | 12 | 2016 | 2410 | 0.380 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2019 | 1642 | 0.340 |
Why?
|
Dendritic Cells | 9 | 2014 | 2747 | 0.330 |
Why?
|
Antineoplastic Agents | 13 | 2022 | 13676 | 0.330 |
Why?
|
Cancer Vaccines | 6 | 2016 | 1041 | 0.320 |
Why?
|
Lymphoma, Primary Effusion | 1 | 2008 | 17 | 0.310 |
Why?
|
Lymphoma, Non-Hodgkin | 5 | 2017 | 1375 | 0.310 |
Why?
|
Hematopoietic Stem Cell Mobilization | 4 | 2017 | 225 | 0.310 |
Why?
|
Multiple Myeloma | 8 | 2013 | 5196 | 0.310 |
Why?
|
Radioimmunotherapy | 4 | 2015 | 93 | 0.290 |
Why?
|
Information Storage and Retrieval | 1 | 2013 | 830 | 0.280 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2012 | 631 | 0.280 |
Why?
|
Mucin-1 | 4 | 2017 | 537 | 0.280 |
Why?
|
Antigens, CD34 | 3 | 2024 | 657 | 0.260 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2006 | 101 | 0.250 |
Why?
|
Lymphoma, Mantle-Cell | 2 | 2020 | 240 | 0.250 |
Why?
|
Anilides | 2 | 2017 | 413 | 0.230 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2017 | 3626 | 0.220 |
Why?
|
Electronic Health Records | 2 | 2019 | 4887 | 0.220 |
Why?
|
Salvage Therapy | 3 | 2021 | 1273 | 0.210 |
Why?
|
Doxorubicin | 6 | 2021 | 2234 | 0.200 |
Why?
|
Nitrogen Mustard Compounds | 2 | 2014 | 44 | 0.200 |
Why?
|
Stem Cell Transplantation | 5 | 2023 | 1596 | 0.190 |
Why?
|
Lymphoma, Follicular | 3 | 2022 | 460 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2022 | 204 | 0.160 |
Why?
|
Hematologic Neoplasms | 3 | 2024 | 1907 | 0.160 |
Why?
|
Etoposide | 4 | 2021 | 639 | 0.150 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6847 | 0.150 |
Why?
|
Radiation Injuries | 1 | 2006 | 1198 | 0.150 |
Why?
|
Health Records, Personal | 1 | 2019 | 127 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 487 | 0.150 |
Why?
|
Leukocytes, Mononuclear | 4 | 2023 | 1854 | 0.140 |
Why?
|
Quinazolinones | 1 | 2019 | 219 | 0.140 |
Why?
|
Databases, Factual | 1 | 2013 | 8080 | 0.140 |
Why?
|
Antigens, CD | 3 | 2014 | 4035 | 0.140 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 263 | 0.140 |
Why?
|
T-Lymphocytes | 5 | 2018 | 10266 | 0.130 |
Why?
|
Dacarbazine | 1 | 2019 | 552 | 0.130 |
Why?
|
Skin Diseases, Parasitic | 1 | 2016 | 13 | 0.130 |
Why?
|
Amebiasis | 1 | 2016 | 33 | 0.130 |
Why?
|
Aged | 33 | 2024 | 171504 | 0.130 |
Why?
|
Boronic Acids | 3 | 2010 | 915 | 0.130 |
Why?
|
Purines | 1 | 2019 | 615 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9419 | 0.120 |
Why?
|
Ifosfamide | 3 | 2013 | 233 | 0.120 |
Why?
|
Humans | 71 | 2024 | 768166 | 0.120 |
Why?
|
Rifamycins | 1 | 2014 | 27 | 0.120 |
Why?
|
Survival Rate | 9 | 2021 | 12840 | 0.120 |
Why?
|
Phenotype | 1 | 2013 | 16726 | 0.120 |
Why?
|
Cell Proliferation | 6 | 2017 | 10474 | 0.120 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 121 | 0.110 |
Why?
|
Miller Fisher Syndrome | 1 | 2014 | 7 | 0.110 |
Why?
|
Transplantation, Homologous | 5 | 2024 | 4833 | 0.110 |
Why?
|
Middle Aged | 40 | 2024 | 223492 | 0.110 |
Why?
|
Pyrazines | 3 | 2010 | 1205 | 0.110 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2017 | 494 | 0.110 |
Why?
|
Cyclophosphamide | 3 | 2021 | 2227 | 0.110 |
Why?
|
Lymphocyte Transfusion | 1 | 2014 | 232 | 0.110 |
Why?
|
Stiff-Person Syndrome | 1 | 2013 | 31 | 0.110 |
Why?
|
Gangliosides | 1 | 2014 | 132 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 614 | 0.110 |
Why?
|
Plasmapheresis | 1 | 2014 | 206 | 0.110 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 210 | 0.100 |
Why?
|
Opportunistic Infections | 1 | 2016 | 375 | 0.100 |
Why?
|
Herpesvirus 3, Human | 1 | 2014 | 159 | 0.100 |
Why?
|
Documentation | 1 | 2019 | 917 | 0.100 |
Why?
|
Antigens, CD1 | 2 | 2008 | 434 | 0.100 |
Why?
|
Immunologic Factors | 2 | 2013 | 1596 | 0.100 |
Why?
|
Methylprednisolone | 1 | 2014 | 386 | 0.100 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2014 | 2055 | 0.100 |
Why?
|
Peptides | 2 | 2015 | 4354 | 0.100 |
Why?
|
Cluster Analysis | 1 | 2019 | 2732 | 0.100 |
Why?
|
Mitoxantrone | 2 | 2003 | 148 | 0.100 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 1015 | 0.100 |
Why?
|
Virus Activation | 1 | 2014 | 324 | 0.100 |
Why?
|
Sulfonamides | 1 | 2021 | 1982 | 0.100 |
Why?
|
Transplantation Conditioning | 1 | 2018 | 1601 | 0.100 |
Why?
|
Heterocyclic Compounds | 1 | 2012 | 245 | 0.090 |
Why?
|
Herpes Zoster | 1 | 2014 | 252 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2021 | 5341 | 0.090 |
Why?
|
Positron-Emission Tomography | 4 | 2015 | 6669 | 0.090 |
Why?
|
Male | 38 | 2024 | 364719 | 0.090 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2016 | 580 | 0.090 |
Why?
|
Cytarabine | 3 | 2020 | 695 | 0.090 |
Why?
|
Leukapheresis | 3 | 2014 | 150 | 0.080 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2015 | 1151 | 0.080 |
Why?
|
Adult | 34 | 2024 | 223646 | 0.080 |
Why?
|
Thalidomide | 2 | 2012 | 886 | 0.080 |
Why?
|
Immunity, Cellular | 2 | 2013 | 1561 | 0.080 |
Why?
|
Antigens, Neoplasm | 2 | 2016 | 1997 | 0.080 |
Why?
|
Autoantigens | 1 | 2014 | 890 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 667 | 0.080 |
Why?
|
Consciousness Disorders | 1 | 2014 | 445 | 0.080 |
Why?
|
Androgen Antagonists | 1 | 1998 | 1412 | 0.080 |
Why?
|
Granzymes | 1 | 2010 | 277 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 2 | 2012 | 3409 | 0.070 |
Why?
|
Vidarabine | 1 | 2009 | 337 | 0.070 |
Why?
|
Female | 40 | 2024 | 397192 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5863 | 0.070 |
Why?
|
Immunophenotyping | 6 | 2013 | 1864 | 0.070 |
Why?
|
International Classification of Diseases | 1 | 2013 | 937 | 0.070 |
Why?
|
Maximum Tolerated Dose | 2 | 2021 | 899 | 0.070 |
Why?
|
Pancreas | 1 | 2014 | 1700 | 0.070 |
Why?
|
Herpesviridae Infections | 1 | 2008 | 269 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1883 | 0.070 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1179 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 921 | 0.070 |
Why?
|
Vaccination | 2 | 2016 | 3437 | 0.070 |
Why?
|
Combined Modality Therapy | 4 | 2014 | 8542 | 0.070 |
Why?
|
Herpesvirus 8, Human | 1 | 2008 | 256 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2735 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2021 | 39348 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1352 | 0.070 |
Why?
|
Glycoproteins | 1 | 2014 | 2202 | 0.060 |
Why?
|
Cell Fusion | 3 | 2011 | 294 | 0.060 |
Why?
|
Cerebellum | 1 | 2013 | 1522 | 0.060 |
Why?
|
Chronic Disease | 5 | 2023 | 9384 | 0.060 |
Why?
|
Pyridines | 1 | 2017 | 2894 | 0.060 |
Why?
|
Intestines | 1 | 2014 | 1909 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1351 | 0.060 |
Why?
|
Prednisone | 2 | 2021 | 1567 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4206 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2121 | 0.060 |
Why?
|
Software | 1 | 2019 | 4478 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2019 | 59629 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2011 | 1895 | 0.060 |
Why?
|
Treatment Outcome | 16 | 2021 | 65371 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2016 | 3114 | 0.060 |
Why?
|
Liposomes | 1 | 2008 | 790 | 0.060 |
Why?
|
Survival Analysis | 5 | 2019 | 10101 | 0.060 |
Why?
|
Pilot Projects | 2 | 2013 | 8741 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1944 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2014 | 3044 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4058 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1042 | 0.050 |
Why?
|
Killer Cells, Natural | 3 | 2008 | 2211 | 0.050 |
Why?
|
Antigens, CD19 | 2 | 2022 | 446 | 0.050 |
Why?
|
Acute Kidney Injury | 1 | 2014 | 1942 | 0.050 |
Why?
|
Apoptosis | 2 | 2015 | 9523 | 0.050 |
Why?
|
Filgrastim | 1 | 2001 | 131 | 0.050 |
Why?
|
Immunotherapy | 3 | 2013 | 4755 | 0.050 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 180 | 0.050 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2008 | 892 | 0.050 |
Why?
|
HIV | 1 | 2008 | 1597 | 0.050 |
Why?
|
Viral Vaccines | 1 | 2006 | 596 | 0.050 |
Why?
|
Immunoenzyme Techniques | 2 | 2015 | 1703 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 414 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5703 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3110 | 0.040 |
Why?
|
Bone Marrow Transplantation | 2 | 1998 | 2709 | 0.040 |
Why?
|
Antibody Formation | 1 | 2005 | 1393 | 0.040 |
Why?
|
Breast Neoplasms | 7 | 2002 | 21206 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11244 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20760 | 0.040 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1837 | 0.040 |
Why?
|
Lymphoma | 1 | 2009 | 1898 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Mice, SCID | 2 | 2015 | 2627 | 0.040 |
Why?
|
Vincristine | 1 | 2021 | 1040 | 0.040 |
Why?
|
Flow Cytometry | 3 | 2015 | 5902 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14164 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 594 | 0.040 |
Why?
|
Clinical Trials as Topic | 4 | 2017 | 8054 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 345 | 0.040 |
Why?
|
Transplantation Immunology | 1 | 2000 | 537 | 0.040 |
Why?
|
Lymphocyte Activation | 4 | 2012 | 5505 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 938 | 0.040 |
Why?
|
Ondansetron | 1 | 1998 | 95 | 0.040 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2007 | 1077 | 0.040 |
Why?
|
Recurrence | 5 | 2014 | 8509 | 0.040 |
Why?
|
Enoxaparin | 1 | 2020 | 391 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 1998 | 115 | 0.040 |
Why?
|
Flutamide | 1 | 1998 | 95 | 0.040 |
Why?
|
Young Adult | 6 | 2024 | 60066 | 0.040 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 1998 | 279 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2923 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 4580 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 188 | 0.030 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 1998 | 131 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5027 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2011 | 1353 | 0.030 |
Why?
|
Drug Administration Schedule | 4 | 2012 | 4860 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2012 | 4573 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2006 | 3474 | 0.030 |
Why?
|
Acanthamoeba castellanii | 1 | 2016 | 9 | 0.030 |
Why?
|
Th2 Cells | 1 | 2001 | 1078 | 0.030 |
Why?
|
Vitamin D | 1 | 2010 | 3311 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15832 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7477 | 0.030 |
Why?
|
Melphalan | 3 | 2002 | 421 | 0.030 |
Why?
|
Glucocorticoids | 2 | 2018 | 2167 | 0.030 |
Why?
|
Carboplatin | 2 | 2013 | 797 | 0.030 |
Why?
|
Vomiting | 1 | 1998 | 655 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 1998 | 11101 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2014 | 1156 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2008 | 11095 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 225 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2024 | 81762 | 0.030 |
Why?
|
NADP | 1 | 2015 | 229 | 0.030 |
Why?
|
Fatigue | 2 | 2012 | 1557 | 0.030 |
Why?
|
Dexamethasone | 2 | 2013 | 1965 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2001 | 2414 | 0.030 |
Why?
|
Cecum | 1 | 2014 | 231 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4648 | 0.030 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2015 | 414 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.030 |
Why?
|
Prognosis | 4 | 2022 | 30010 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2017 | 1340 | 0.030 |
Why?
|
Mutation | 1 | 2017 | 30238 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 716 | 0.030 |
Why?
|
Glutathione | 1 | 2015 | 589 | 0.030 |
Why?
|
Nitriles | 1 | 1998 | 980 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1512 | 0.020 |
Why?
|
Treatment Failure | 2 | 2013 | 2661 | 0.020 |
Why?
|
Metalloendopeptidases | 1 | 1993 | 386 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1737 | 0.020 |
Why?
|
Blood Component Removal | 1 | 2012 | 132 | 0.020 |
Why?
|
Th1-Th2 Balance | 1 | 2011 | 38 | 0.020 |
Why?
|
Benzylamines | 1 | 2012 | 251 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2001 | 6514 | 0.020 |
Why?
|
Immunization | 2 | 2006 | 1219 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 998 | 0.020 |
Why?
|
Immune System | 1 | 2016 | 799 | 0.020 |
Why?
|
Time Factors | 5 | 2017 | 40218 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22371 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2016 | 1836 | 0.020 |
Why?
|
Thorax | 1 | 2014 | 557 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2015 | 12800 | 0.020 |
Why?
|
Necrosis | 1 | 2015 | 1616 | 0.020 |
Why?
|
Carcinoma | 2 | 2002 | 2332 | 0.020 |
Why?
|
Lymphocyte Culture Test, Mixed | 2 | 2001 | 510 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2014 | 19015 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2016 | 863 | 0.020 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 70 | 0.020 |
Why?
|
Observation | 1 | 2011 | 310 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1419 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 355 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 2 | 2012 | 1815 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1733 | 0.020 |
Why?
|
Mitogens | 1 | 2010 | 229 | 0.020 |
Why?
|
Cell Communication | 1 | 2017 | 1660 | 0.020 |
Why?
|
Cohort Studies | 4 | 2018 | 41754 | 0.020 |
Why?
|
Adolescent | 4 | 2024 | 89169 | 0.020 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 251 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1998 | 1536 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1061 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 160 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1647 | 0.020 |
Why?
|
Axilla | 2 | 2006 | 623 | 0.020 |
Why?
|
Atrophy | 1 | 2014 | 1646 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 315 | 0.020 |
Why?
|
Retreatment | 1 | 2010 | 598 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 1998 | 2463 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7243 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1609 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6124 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1321 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 892 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2015 | 2149 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2521 | 0.020 |
Why?
|
Myelodysplastic Syndromes | 1 | 2017 | 1399 | 0.020 |
Why?
|
Cisplatin | 1 | 2013 | 1660 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3611 | 0.020 |
Why?
|
Cell Polarity | 1 | 2010 | 639 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2614 | 0.020 |
Why?
|
Colon | 1 | 2014 | 1801 | 0.020 |
Why?
|
Clone Cells | 1 | 2010 | 1670 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 2010 | 498 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2014 | 13014 | 0.020 |
Why?
|
Drug Resistance | 1 | 2011 | 1599 | 0.020 |
Why?
|
Sirolimus | 1 | 2012 | 1540 | 0.020 |
Why?
|
Lymphoproliferative Disorders | 1 | 2009 | 528 | 0.020 |
Why?
|
Disease Progression | 3 | 2011 | 13671 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10760 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2892 | 0.010 |
Why?
|
Animals | 4 | 2017 | 169246 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2014 | 1791 | 0.010 |
Why?
|
Tissue Donors | 1 | 2014 | 2381 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 4030 | 0.010 |
Why?
|
Anticoagulants | 1 | 2020 | 4852 | 0.010 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 1625 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2010 | 1251 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2006 | 963 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1801 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2015 | 3139 | 0.010 |
Why?
|
Mice | 3 | 2017 | 82029 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2004 | 199 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2006 | 517 | 0.010 |
Why?
|
Lymphatic Metastasis | 2 | 2006 | 2914 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 334 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2004 | 866 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4352 | 0.010 |
Why?
|
Anemia | 1 | 2012 | 1514 | 0.010 |
Why?
|
Neoplasm Metastasis | 3 | 2002 | 4912 | 0.010 |
Why?
|
Pain | 2 | 2010 | 5100 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Cell Separation | 1 | 2008 | 1728 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2007 | 1528 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6793 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 85 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18412 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 367 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3160 | 0.010 |
Why?
|
Gene Expression | 1 | 1993 | 7598 | 0.010 |
Why?
|
MicroRNAs | 1 | 2017 | 3803 | 0.010 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 165 | 0.010 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 114 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 529 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17140 | 0.010 |
Why?
|
Prospective Studies | 3 | 2014 | 54926 | 0.010 |
Why?
|
Signal Transduction | 2 | 2015 | 23645 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 491 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2006 | 1281 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 410 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1479 | 0.010 |
Why?
|
Skin Tests | 1 | 2000 | 639 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2002 | 2000 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2010 | 4415 | 0.010 |
Why?
|
United States | 2 | 2018 | 73039 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 9015 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 752 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 22291 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1617 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2000 | 855 | 0.010 |
Why?
|
Bone Marrow | 1 | 2007 | 2935 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1652 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2013 | 11669 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3074 | 0.010 |
Why?
|
Methotrexate | 1 | 2002 | 1721 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1536 | 0.010 |
Why?
|
Immunity | 1 | 2000 | 1003 | 0.010 |
Why?
|
Matrix Metalloproteinase 11 | 1 | 1993 | 15 | 0.010 |
Why?
|
Cathepsin D | 1 | 1993 | 59 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2002 | 2846 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1993 | 1550 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74944 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12077 | 0.000 |
Why?
|
Carcinoma in Situ | 1 | 1993 | 788 | 0.000 |
Why?
|
Cell Line | 1 | 2001 | 15597 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12543 | 0.000 |
Why?
|
Cytokines | 1 | 2001 | 7453 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7577 | 0.000 |
Why?
|
Melanoma | 1 | 1985 | 5706 | 0.000 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1993 | 1099 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1993 | 2253 | 0.000 |
Why?
|
Culture Techniques | 1 | 1985 | 530 | 0.000 |
Why?
|
Child, Preschool | 1 | 2005 | 42669 | 0.000 |
Why?
|
Mitosis | 1 | 1985 | 1178 | 0.000 |
Why?
|
Cell Division | 1 | 1985 | 4473 | 0.000 |
Why?
|
Child | 1 | 2005 | 80917 | 0.000 |
Why?
|
Scrotum | 1 | 1952 | 117 | 0.000 |
Why?
|
Dissection | 1 | 1952 | 299 | 0.000 |
Why?
|
Food | 1 | 1952 | 768 | 0.000 |
Why?
|
Lymph Node Excision | 1 | 1952 | 1271 | 0.000 |
Why?
|